IP Library › Granted Patent US 7,612,082
Granted Patent B2
US 7,612,082 · App. 10/976,442 · Granted Nov 3, 2009

Prostaglandin EP

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,612,082
App. No.
10/976,442
Granted
Nov 3, 2009
Kind
B2
Abstract

Disclosed herein are methods and compositions related to compound 1 or compound 2 or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP 4 receptor, or are prostaglandin EP 4 antagonists.

Claims (5)

1. A method of treating an EP 4 receptor mediated condition comprising administering a therapeutically effective amount of a compound to a mammal in need thereof, wherein said compound has a formula

or a pharmaceutically acceptable salt thereof; and

wherein said EP 4 receptor mediated condition is an ocular disease, wherein said ocular disease is glaucoma.

2. A method comprising treating glaucoma by administering to a mammal suffering from glaucoma a compound comprising

or a pharmaceutically acceptable salt thereof.

Assignments (2)
SECURITY AGREEMENT Recorded Mar 22, 2006
From: WING ENTERPRISES, INCORPORATED
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 017681/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2004
From: WHEELER, LARRY A.; GARST, MICHAEL E.; LIANG, YANBIN; WOODWARD, DAVID; KRAUSS, ACHIM H.-P; BURK, ROBERT M.; DONDE, YARIV; HOLOBOSKI, MARK; OLD, DAVID W.; CHEN, JUNE
To: ALLERGAN, INC.
Reel/Frame 015951/0463 →